Bayer strikes $2.45 billion deal for breakthrough blindness drug developer Perfuse Therapeutics
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
The acquisition gives Bayer full rights to PER-001, an experimental therapy now in Phase II clinical trials for Glaucoma and Diabetic Retinopathy
Approval strengthens the company’s growing international anti-infective portfolio
The initiative by DKMS Foundation India is for below 12 years children suffering from transfusion-dependent thalassemia
The formulation contains 0.075% Capsaicin, a clinically proven ingredient along with menthol, camphor and eucalyptus oil
At the center of the deal is TERN-701, a drug recently granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration for adults with Philadelphia chromosome-positive chronic myeloid leukemia
The standout story remains Wegovy, particularly its new oral formulation
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
The kidney care provider has established over 40 dialysis centres, delivering more than 40,000 dialysis sessions
More than 3,500 participants will join the nationwide AI-focused hackathon hosted as Indian Institute of Science
Subscribe To Our Newsletter & Stay Updated